Minerva Neurosciences Inc (NERV)

0.372
-0.019(-4.86%)
  • Volume:
    52,314
  • Day's Range:
    0.350 - 0.389
  • 52 wk Range:
    0.331 - 3.140

NERV Overview

Prev. Close
0.391
Day's Range
0.35-0.389
Revenue
-
Open
0.389
52 wk Range
0.331-3.14
EPS
-1.19
Volume
52,314
Market Cap
15.9M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
88,759
P/E Ratio
-
Beta
1.21
1-Year Change
-88.04%
Shares Outstanding
42,721,566
Next Earnings Date
03 Aug 2022
What is your sentiment on Minerva Neurosciences?
or
Market is currently closed. Voting is open during market hours.

Minerva Neurosciences Inc News

Minerva Neurosciences Inc Company Profile

Minerva Neurosciences Inc Company Profile

Employees
9

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell